anti-Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Antikörper

The vesicular monoamine transporter acts to accumulate cytosolic monoamines into synaptic vesicles, using the proton gradient maintained across the synaptic vesicular membrane.

Alle Antikörper anzeigen Gen GeneID UniProt
Anti-Human Slc18a2 Slc18a2 6571 Q05940
Anti-Ratte Slc18a2 Slc18a2 25549 Q01827
Anti-Maus Slc18a2 Slc18a2 214084 Q8BRU6
Direkt bei antikoerper-online bestellen
  • +49 (0)241 95 163 153
  • +49 (0)241 95 163 155
  • Online bestellen
  • orders@antikoerper-online.de

Weitere Antikörper gegen Solute Carrier Family 18 (Vesicular Monoamine), Member 2 Interaktionspartner

Zebrafish Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Interaktionspartner

  1. Taken together, these findings suggest that Vmat2 heterzygous mutant zebrafish may serve as a new model of anxiety, which may be related with the low level of DA, 5-HT (zeige DDC Antikörper) and NE.

Rhesus Monkey Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Interaktionspartner

  1. these results in rhesus monkey clearly demonstrated a reduction in VMAT2 binding in the striatum following prolonged exposure to cocaine.

Fruit Fly (Drosophila melanogaster) Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Interaktionspartner

  1. This study identify VMAT as an important regulator of sleep in Drosophila and demonstrate that small-molecule screens provide an effective approach to identify genes and pathways that impact adult Drosophila behavior.

  2. Interaction between vesicular monoamine transporter and pesticides in vivo does not increase survival of fruit flies exposed to rotenone but blocks the loss of dopaminergic neurons caused by the pesticide.

  3. A novel mRNA splice variant of Drosophila VMAT (DVMAT-B) is expressed not in neurons but rather in a small subset of glia in the lamina of the fly's optic lobe.

Human Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Interaktionspartner

  1. Study found that 2 promoter regions of Vesicular monoamine transporter 2 (hVMAT2) are associated with Parkinson's disease. Study shows that low-activity haplotypes may confer more vulnerability in the presence of a neurotoxin and that hVMAT2 activity could be inhibited by DNA methylation (zeige HELLS Antikörper) in human dopaminergic neurons.

  2. No statistically significant differences were found between cases and controls for the allele frequencies in five genes: TH, SLC18A2, DRD1 (zeige DRD1 Antikörper), DRD3 (zeige DRD3 Antikörper) and COMT (zeige COMT Antikörper). Conversely, some alleles of the 12 sNPs from the DRD2 (zeige DRD2 Antikörper) locus and the 5 from the MAOA (zeige MAOA Antikörper) locus showed significant associations with excessive alcohol consumption.

  3. VMAT1 (zeige SLC18A1 Antikörper) and VMAT2 are expressed in the majority of neuroblastomas

  4. describe a second case of infantile-onset movement disorder caused by a different mutation in SLC18A2 compared to PMID:23363473, and partial improvement of symptoms upon treatment with pramipexole; supports identification of causal mutation in index case.

  5. Two SNPs (rs10082463 & rs363285) of SLC18A2 were nominally associated with cognition.

  6. The finding of this study provide support for a role of VMAT2 in tardive dyskinesia and add to evidence that VMAT2 may be a potential therapeutic target in the treatment of TD.

  7. VMAT2 genetic variants contribute to the phenotypes of alcohol dependence.

  8. Genetic variation in VMAT2 may be linked to alterations in cognitive functioning underlying psychotic disorder, possibly through altered transport of monoamines into synaptic vesicles.

  9. In an Italian cohort, variability in VMAT2 promoter region appears to confer a reduced risk of developing Parkinson's disease.

  10. VMAT2 expression dynamically decreased in the neocortex of temporal lobe epilepsy patients when compared with the control subjects.

Mouse (Murine) Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Interaktionspartner

  1. In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of Parkinson's disease .

  2. Intravenous use of a psychostimulant drug containing methcathinone (ephedrone) and manganese causes an irreversible extrapyramidal syndrome; study reproduced the syndrome in mice to evaluate dopaminergic damage. Increased [(11)C]dihydrotetrabenazine binding may indicate vesicular monoamine transporter type 2 (VMAT2) function is altered.

  3. In contrast to their loss of catecholamine neurons of the substantia nigra and locus ceruleus, aged VMAT2 LO mice do not exhibit a change in the number of serotonergic (TPH2 (zeige TPH2 Antikörper)+) neurons within the dorsal raphe

  4. Rotenone induces dopamine neuron death through a series of sequential events including microtubule destabilization, JNK3 (zeige MAPK10 Antikörper) activation, VMAT2 inhibition, accumulation of cytosolic dopamine, and generation of ROS (zeige ROS1 Antikörper).

  5. increased release of dopamine and neuroprotection from MPTP (zeige PTPN2 Antikörper) toxicity in the VMAT2-overexpressing mice suggest that interventions aimed at enhancing vesicular capacity may be of therapeutic benefit in Parkinson disease

  6. The coordinate loss of dopamine and norepinephrine neurons in VMAT2 LO mice parallels the pattern of neurodegeneration that occurs in human PD.

  7. findings support the idea that altered DAT (zeige SLC6A3 Antikörper) and VMAT2 expression affect age-related changes in dopaminergic function.

  8. Data suggest that pancreatic islets of mice and rats do not contain VMAT2, except in mast cells and sympathetic nerve terminals that innervate the islets.

  9. VMAT2 expression was increased by Nurr1 (zeige NR4A2 Antikörper) gene activation in lactacystin-lesioned mice.

  10. Data show that alpha-synuclein (zeige SNCA Antikörper) transcription is inversely correlated with neurite growth and VMAT2 expression, and inhibition of RhoA (zeige RHOA Antikörper) leads to a decrease in alpha-synuclein (zeige SNCA Antikörper).

Solute Carrier Family 18 (Vesicular Monoamine), Member 2 (Slc18a2) Antigen-Profil

Protein Überblick

The vesicular monoamine transporter acts to accumulate cytosolic monoamines into synaptic vesicles, using the proton gradient maintained across the synaptic vesicular membrane. Its proper function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders. The transporter is a site of action of important drugs, including reserpine and tetrabenazine (summary by Peter et al., 1993

Genbezeichner und Symbole assoziert mit Slc18a2

  • solute carrier family 18 (vesicular monoamine), member 2 (slc18a2) Antikörper
  • solute carrier family 18 (vesicular monoamine), member 2 (SLC18A2) Antikörper
  • solute carrier family 18 (vesicular monoamine transporter), member 2 (slc18a2) Antikörper
  • solute carrier family 18 (vesicular monoamine), member 2 (LOC100228266) Antikörper
  • Vesicular monoamine transporter (Vmat) Antikörper
  • vesicular monoamine transporter (CpipJ_CPIJ007766) Antikörper
  • solute carrier family 18 (vesicular monoamine transporter), member 2 (SLC18A2) Antikörper
  • solute carrier family 18 (vesicular monoamine transporter), member 2 (Slc18a2) Antikörper
  • solute carrier family 18 (vesicular monoamine), member 2 (Slc18a2) Antikörper
  • 1110037L13Rik Antikörper
  • 9330105E13 Antikörper
  • CG6119 Antikörper
  • CG6139 Antikörper
  • CG33528 Antikörper
  • Dmel\\CG33528 Antikörper
  • dVMAT Antikörper
  • DVMAT-A Antikörper
  • DVMAT-B Antikörper
  • l(2)SH0459 Antikörper
  • l(2)SH2 0459 Antikörper
  • MGC69173 Antikörper
  • MNAT Antikörper
  • SLC18A2 Antikörper
  • SVAT Antikörper
  • SVMT Antikörper
  • VAT2 Antikörper
  • VMAT Antikörper
  • VMAT-2 Antikörper
  • Vmat2 Antikörper

Bezeichner auf Proteinebene für Slc18a2

solute carrier family 18 (vesicular monoamine), member 2 , vesicular monoamine transporter , synaptic vesicular amine transporter , vmat2 , synaptic vesicular amine transporter-like , CG33528-PC , CG33528-PD , CG33528-PE , CG33528-PF , Vmat-PC , Vmat-PD , Vmat-PE , Vmat-PF , drosophila vesicular monoamine transporter , lethal (2) SH0459 , vesicle transporter , monoamine neurotransmitter transporter , monoamine transporter , solute carrier family 18 member 2 , vesicle monoamine transporter type 2 , vesicle monoamine/H+ antiporter , vesicular amine transporter 2 , Solute carrier family 18 A2 (vesicular monoamine transporter 2) , VAT2 , solute carrier family 18, member 2 , vesicular monoamine transporter 2

GENE ID SPEZIES
379730 Xenopus laevis
423921 Gallus gallus
448192 Xenopus (Silurana) tropicalis
466213 Pan troglodytes
553304 Danio rerio
701133 Macaca mulatta
100228266 Taeniopygia guttata
100447972 Pongo abelii
100550038 Meleagris gallopavo
3346192 Drosophila melanogaster
6039714 Culex quinquefasciatus
6571 Homo sapiens
25549 Rattus norvegicus
214084 Mus musculus
282471 Bos taurus
486908 Canis lupus familiaris
Haben Sie etwas anderes gesucht?